New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier?
about
Next generation of weight management medications: implications for diabetes and CVD riskCulture, psychosomatics and substance abuse: the example of body image drugsEmerging pharmacotherapy for obesity.Effects of chemosignals from sad tears and postprandial plasma on appetite and food intake in humans.Can We Selectively Reduce Appetite for Energy-Dense Foods? An Overview of Pharmacological Strategies for Modification of Food Preference BehaviorPublic views on food addiction and obesity: implications for policy and treatmentCharacterization of the 5-HT2C receptor agonist lorcaserin on efficacy and safety measures in a rat model of diet-induced obesity.The utility of animal models to evaluate novel anti-obesity agents.Rhein Reduces Fat Weight in db/db Mouse and Prevents Diet-Induced Obesity in C57Bl/6 Mouse through the Inhibition of PPARγ Signaling.Directly Observable Behavioral Effects of Lorcaserin in RatsBeta-Glucan-Rich Extract from Pleurotus sajor-caju (Fr.) Singer Prevents Obesity and Oxidative Stress in C57BL/6J Mice Fed on a High-Fat Diet.Peptide inhibitors disrupt the serotonin 5-HT2C receptor interaction with phosphatase and tensin homolog to allosterically modulate cellular signaling and behavior.Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes.New drug targets for the treatment of obesity.An overview of treatments for obesity in a population with mental illness.Anti-obesity drugs: past, present and future.5-hydroxytryptamine medications for the treatment of obesity.A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents.Exploring structural requirements for peripherally acting 1,5-diaryl pyrazole-containing cannabinoid 1 receptor antagonists for the treatment of obesity.Plantago asiatica L. Seed Extract Improves Lipid Accumulation and Hyperglycemia in High-Fat Diet-Induced Obese Mice.Sympathomimetic activity of a Hoodia gordonii product: a possible mechanism of cardiovascular side effects.Obesity Drug Update: The Lost Decade?Role of impulsivity and reward in the anti-obesity actions of 5-HT2C receptor agonists.Lorcaserin and CP-809101 reduce motor impulsivity and reinstatement of food seeking behavior in male rats: Implications for understanding the anti-obesity property of 5-HT2C receptor agonists.Neural circuits of eating behaviour: Opportunities for therapeutic development.Behavioural profile of exendin-4/naltrexone dose combinations in male rats during tests of palatable food consumption.Acute behavioural effects of bupropion and naltrexone, alone and in combination, in non-deprived male rats presented with palatable mash.Low dose naloxone attenuates the pruritic but not anorectic response to rimonabant in male rats.Milk protein hydrolysates activate 5-HT2C serotonin receptors: influence of the starting substrate and isolation of bioactive fractions
P2860
Q28082858-3DBA002C-527E-4978-B78D-50F8336FA84DQ28728748-CDF02EFA-E0B1-427C-8F12-2E7A7F7B016CQ34207458-3B5AD878-308C-4128-9A53-FC712D32DCB1Q34369466-75C0C751-62C6-40B5-B9DE-1FD0FCC9C350Q34501087-2C397FE0-F476-4ACF-8428-060D3254B632Q35005181-5FD964FA-3A73-4217-9340-D443F0DADCFDQ35049574-4EC34251-374B-4D94-89F0-7817A61435E2Q35589958-C4614CDA-495A-47CF-884E-A21EE2DC536AQ36294278-0D6A73EB-9C5F-444C-9624-B5EE68034AA8Q36316458-9ABCA621-B2DA-43CF-B4FD-47F6BE02BED1Q36869289-FE5CD547-34F7-4FFB-B097-6F6847D5DE33Q37014106-2FCE0161-0794-48B9-904B-E95179FB1FF4Q37102861-C753EE6F-17C2-49B0-97BE-CD44840788B1Q37886661-DD943682-739B-47A1-BC47-1B89C824F57EQ37980571-BA1155EB-756C-456B-94DF-303F94C82126Q38036925-C61B4F9F-4135-49C3-B885-4F77DD9A60B4Q38449992-FFF77A71-3B0A-4243-8F6F-FE6D135E13C9Q38544824-C0208119-7232-4FF9-9867-6051F46E7B07Q40726993-44022A95-4E2E-4334-8713-1EADECE2ED6DQ41181654-865C6C1E-1D5C-4E1D-9789-213729D1D985Q41789269-FD9770CF-FC99-4462-8751-A77BACD4B9EAQ46972562-83C77034-1A78-4AF9-9D47-B939BDC04670Q47588598-548EB19E-6728-4F55-B097-B7418CE9855DQ48013285-475796F0-D8F2-42DC-AC1E-024FF83C349CQ50046451-5BDE1861-5077-4DF7-8B65-47EE596EDA59Q51744991-79CBBB0B-386A-4B24-AE8C-F4E3351CBCFEQ52638749-CC65133C-2C0D-456F-8FD5-5447F0501E3FQ52842340-D298DC16-86BE-4A35-A563-82A42912B0FBQ57513421-EEEDD25E-4C56-4095-9B7B-923D22886F2E
P2860
New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier?
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
New approaches to the pharmaco ...... through the efficacy barrier?
@ast
New approaches to the pharmaco ...... through the efficacy barrier?
@en
New approaches to the pharmaco ...... through the efficacy barrier?
@nl
type
label
New approaches to the pharmaco ...... through the efficacy barrier?
@ast
New approaches to the pharmaco ...... through the efficacy barrier?
@en
New approaches to the pharmaco ...... through the efficacy barrier?
@nl
prefLabel
New approaches to the pharmaco ...... through the efficacy barrier?
@ast
New approaches to the pharmaco ...... through the efficacy barrier?
@en
New approaches to the pharmaco ...... through the efficacy barrier?
@nl
P1476
New approaches to the pharmaco ...... through the efficacy barrier?
@en
P2093
G A Kennett
P356
10.1016/J.PBB.2010.07.020
P407
P50
P577
2010-08-03T00:00:00Z